Predicting Antitumor Effect via EGF Dependency Evaluation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack an effective way to predict the antitumor effect of angiogenesis inhibitors before administration, leading to inefficient treatment and potential adverse effects, and there is a need for identifying specific substances with VEGF and EGF inhibitory activities that are effective in cancer treatment.
Innovation Solution
Evaluating the EGF dependency of tumor cells for proliferation and survival using indicators such as EGF receptor expression and phosphorylation levels to predict the antitumor effect of angiogenesis inhibitors, and combining VEGF receptor kinase inhibitors with EGF inhibitors for enhanced antitumor activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If angiogenesis inhibitors are administered to treat cancer, then antitumor effect is improved, but treatment efficiency is worsened due to inability to predict effectiveness beforehand
Solution Approach 1:
The invention performs preliminary evaluation of EGF dependency in tumor cells before administering angiogenesis inhibitors. By assessing EGF receptor expression levels and phosphorylation states in advance, the method predicts which patients will respond to treatment, allowing clinicians to avoid ineffective treatments and allocate resources efficiently.
Solution Approach 2:
The invention prepares for potential treatment failure by establishing predictive biomarkers (EGF dependency indicators) before treatment begins. This allows for early identification of non-responders, preventing waste of time and resources on ineffective therapies and allowing alternative treatments to be considered proactively.
2Reliability
If combination therapy with VEGF inhibitor and EGF inhibitor is used, then antitumor efficacy is improved, but treatment complexity is worsened
Solution Approach 1:
The invention applies local quality by targeting specific molecular pathways (EGF and VEGF signaling) that are locally overactive in certain tumor types. By identifying tumors with high EGF dependency through biomarker analysis, the treatment is precisely directed at the relevant molecular subset, making the combination therapy more justified and manageable.
Solution Approach 2:
The invention changes the parameter of treatment selection from empirical to molecular-based. By measuring EGF receptor expression and phosphorylation levels, the treatment approach transitions from general angiogenesis inhibition to targeted combination therapy based on molecular parameters, thereby justifying the increased complexity through improved efficacy.
Data Source
AI summary
The present invention provides a method of predicting the antitumor effect of an angiogenesis inhibitor. It is possible to predict the antitumor effect of an angiogenesis inhibitor by evaluating the EGF dependency of a tumor cell for proliferation and/or survival and using the EGF dependency as an indicator. Since the antitumor effect of an angiogenesis inhibitor correlates with the EGF dependency of a tumor cell for proliferation and/or survival, the angiogenesis inhibitors is capable of producing excellent antitumor effect when combined with a substance having EGF inhibitory activity.